• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胰腺癌切除术后腹膜复发的预测风险因素及其预防策略。

Predictive risk factors for peritoneal recurrence after pancreatic cancer resection and strategies for its prevention.

作者信息

Ariake Kyohei, Motoi Fuyuhiko, Ohtsuka Hideo, Fukase Koji, Masuda Kunihiro, Mizuma Masamichi, Hayashi Hiroki, Nakagawa Kei, Morikawa Takanori, Maeda Shimpei, Takadate Tatsuyuki, Naitoh Takeshi, Egawa Shinichi, Unno Michiaki

机构信息

Department of Surgery, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.

Division of International Cooperation for Disaster Medicine, Tohoku Medical Megabank Organization, 2-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.

出版信息

Surg Today. 2017 Dec;47(12):1434-1442. doi: 10.1007/s00595-017-1531-9. Epub 2017 Apr 22.

DOI:10.1007/s00595-017-1531-9
PMID:28434080
Abstract

PURPOSE

To evaluate the risk factors for peritoneal recurrence (PR) of pancreatic adenocarcinoma and to discuss the appropriate management strategies.

METHODS

We reviewed the medical records of 236 patients who underwent pancreatectomy for pancreatic adenocarcinoma. We then compared the clinicopathological characteristics of patients with vs. those without PR. The independent risk factors for PR were defined using the Cox proportional hazards regression model.

RESULTS

The median survival of patients with PR was 13.3 months after surgical treatment. The PR group had a significantly higher incidence of portal vein resection, longer operative time (≥648 min), greater blood loss (≥2179 mL), blood transfusion, tumor size, portal vein invasion, artery invasion, pancreatic nerve plexus invasion, and histological grade. Multivariate analysis revealed that excessive blood loss (≥2179 mL; P = 0.010), artery invasion (P = 0.025), pancreatic nerve plexus invasion (P = 0.001), and histological grade 3 (P = 0.011) were independent risk factors for PR. Excessive blood loss was also strongly related to tumor size (P = 0.018).

CONCLUSIONS

Local invasion and tumor size-related factors suggested the possibility of intraoperative dissemination at the time of tumor resection. Preoperative treatment and an operative procedure to prevent tumor exposure may help prevent PR.

摘要

目的

评估胰腺腺癌腹膜复发(PR)的危险因素,并探讨合适的治疗策略。

方法

我们回顾了236例行胰腺切除术治疗胰腺腺癌患者的病历。然后比较了有PR与无PR患者的临床病理特征。使用Cox比例风险回归模型确定PR的独立危险因素。

结果

PR患者手术治疗后的中位生存期为13.3个月。PR组门静脉切除率、手术时间更长(≥648分钟)、失血量更大(≥2179毫升)、输血、肿瘤大小、门静脉侵犯、动脉侵犯、胰腺神经丛侵犯和组织学分级的发生率显著更高。多因素分析显示,失血量过多(≥2179毫升;P = 0.010)、动脉侵犯(P = 0.025)、胰腺神经丛侵犯(P = 0.001)和组织学3级(P = 0.011)是PR的独立危险因素。失血量过多也与肿瘤大小密切相关(P = 0.018)。

结论

局部侵犯和与肿瘤大小相关的因素提示肿瘤切除时术中播散的可能性。术前治疗和防止肿瘤暴露的手术操作可能有助于预防PR。

相似文献

1
Predictive risk factors for peritoneal recurrence after pancreatic cancer resection and strategies for its prevention.胰腺癌切除术后腹膜复发的预测风险因素及其预防策略。
Surg Today. 2017 Dec;47(12):1434-1442. doi: 10.1007/s00595-017-1531-9. Epub 2017 Apr 22.
2
The prognostic significance of lymph node metastasis and intrapancreatic perineural invasion in pancreatic cancer after curative resection.根治性切除术后胰腺癌中淋巴结转移和胰腺内神经周围侵犯的预后意义
Surg Today. 1999;29(1):16-22. doi: 10.1007/BF02482964.
3
Locally advanced pancreatic duct adenocarcinoma: pancreatectomy with planned arterial resection based on axial arterial encasement.局部进展期胰腺导管腺癌:基于轴向动脉包绕情况行计划性动脉切除的胰腺切除术
Langenbecks Arch Surg. 2016 Dec;401(8):1131-1142. doi: 10.1007/s00423-016-1488-y. Epub 2016 Jul 30.
4
Survival benefits of portal vein resection for pancreatic cancer.胰腺癌门静脉切除的生存获益
Am J Surg. 2003 Aug;186(2):149-53. doi: 10.1016/s0002-9610(03)00173-9.
5
Portal vein resection in pancreatic head carcinoma. Part 2: Clinical significance.胰头癌的门静脉切除。第2部分:临床意义。
Hepatogastroenterology. 2001 May-Jun;48(39):888-91.
6
Pancreatectomy with Mesenteric and Portal Vein Resection for Borderline Resectable Pancreatic Cancer: Multicenter Study of 406 Patients.肠系膜和门静脉切除的胰切除术治疗可切除边缘性胰腺癌:406例患者的多中心研究
Ann Surg Oncol. 2016 Jun;23(6):2028-37. doi: 10.1245/s10434-016-5123-5. Epub 2016 Feb 18.
7
En bloc vascular resection for locally advanced pancreatic malignancies infiltrating major blood vessels: perioperative outcome and long-term survival in 136 patients.局部晚期浸润主要血管的胰腺恶性肿瘤的整块血管切除术:136例患者的围手术期结局和长期生存情况
Ann Surg. 2008 Feb;247(2):300-9. doi: 10.1097/SLA.0b013e31815aab22.
8
Results of pancreatic resection associated with portal vein resection in an Australian tertiary care centre.澳大利亚一家三级医疗中心中与门静脉切除相关的胰腺切除术结果。
ANZ J Surg. 2015 Apr;85(4):270-3. doi: 10.1111/ans.12585. Epub 2014 Apr 9.
9
Pancreatic adenocarcinoma with venous involvement: is up-front synchronous portal-superior mesenteric vein resection still justified? A survey of the Association Française de Chirurgie.伴有静脉受累的胰腺腺癌: upfront同步门静脉-肠系膜上静脉切除仍合理吗?法国外科协会的一项调查
Ann Surg Oncol. 2015;22(6):1874-83. doi: 10.1245/s10434-014-4304-3. Epub 2015 Feb 10.
10
Hepatectomy and pancreatectomy with combined vascular resection in patients with hepato-biliary and pancreas diseases at a single cancer institute.单一癌症研究所对肝胆胰疾病患者进行的肝切除及联合血管切除的胰腺切除术
Hepatogastroenterology. 2008 May-Jun;55(84):873-8.

引用本文的文献

1
Postoperative Carbohydrate Antigen 19-9 Level as a Good Indicator of Ineffective Response to the Currently Recommended S-1 Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma: A Single-Center, Retrospective Study.术后糖类抗原 19-9 水平作为目前推荐的胰腺导管腺癌 S-1 辅助化疗无效反应的良好指标:一项单中心回顾性研究。
Ann Surg Oncol. 2024 Jan;31(1):525-534. doi: 10.1245/s10434-023-14440-0. Epub 2023 Oct 18.
2
Isolated pulmonary metastases in pancreatic ductal adenocarcinoma: a review of current evidence.孤立性肺转移瘤在胰腺导管腺癌中的研究现状。
Cancer Biol Ther. 2023 Dec 31;24(1):2198479. doi: 10.1080/15384047.2023.2198479.
3

本文引用的文献

1
A novel preoperative predictor of pancreatic fistula using computed tomography after distal pancreatectomy with staple closure.一种使用计算机断层扫描的新型胰瘘术前预测指标,用于吻合器闭合的远端胰腺切除术后。
Surg Today. 2017 Oct;47(10):1180-1187. doi: 10.1007/s00595-017-1495-9. Epub 2017 Mar 6.
2
Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma.术前放化疗不会影响胰腺导管腺癌患者辅助化疗的可行性。
Surg Today. 2017 Feb;47(2):218-226. doi: 10.1007/s00595-016-1405-6. Epub 2016 Sep 1.
3
Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients.
The value of enhanced CT features and texture-signatures in assessing the inflammatory infiltration of pancreatic ductal adenocarcinoma.
增强CT特征和纹理特征在评估胰腺导管腺癌炎症浸润中的价值
Front Oncol. 2023 Feb 3;13:1078861. doi: 10.3389/fonc.2023.1078861. eCollection 2023.
4
Development of the Peritoneal Metastasis: A Review of Back-Grounds, Mechanisms, Treatments and Prospects.腹膜转移的发展:背景、机制、治疗与前景综述
J Clin Med. 2022 Dec 23;12(1):103. doi: 10.3390/jcm12010103.
5
Recurrence and Prognostic Value of Circulating Tumor Cells in Resectable Pancreatic Head Cancer: A Single Center Retrospective Study.可切除性胰头癌中循环肿瘤细胞的复发及预后价值:一项单中心回顾性研究
Front Surg. 2022 Apr 6;9:832125. doi: 10.3389/fsurg.2022.832125. eCollection 2022.
6
Prediction of Recurrence Pattern of Pancreatic Cancer Post-Pancreatic Surgery Using Histology-Based Supervised Machine Learning Algorithms: A Single-Center Retrospective Study.使用基于组织学的监督机器学习算法预测胰腺癌胰腺切除术后的复发模式:一项单中心回顾性研究。
Ann Surg Oncol. 2022 Mar 1. doi: 10.1245/s10434-022-11471-x.
7
Stomatin‑like protein 2 induces metastasis by regulating the expression of a rate‑limiting enzyme of the hexosamine biosynthetic pathway in pancreatic cancer.基质细胞衍生因子 2 通过调节胰腺癌中己糖胺生物合成途径的限速酶表达诱导转移。
Oncol Rep. 2021 Jun;45(6). doi: 10.3892/or.2021.8041. Epub 2021 Apr 13.
8
A novel intraperitoneal therapy for gastric cancer with DFP-10825, a unique RNAi therapeutic targeting thymidylate synthase, in a peritoneally disseminated xenograft model.一种新型的胃癌腹腔内治疗方法,使用 DFP-10825(一种针对胸苷酸合成酶的独特 RNAi 治疗药物),在腹膜播散的异种移植模型中。
Cancer Med. 2019 Dec;8(17):7313-7321. doi: 10.1002/cam4.2598. Epub 2019 Oct 14.
9
Analysis of lncRNA-mRNA networks after MEK1/2 inhibition based on WGCNA in pancreatic ductal adenocarcinoma.基于 WGCNA 的 MEK1/2 抑制后胰腺导管腺癌 lncRNA-mRNA 网络分析。
J Cell Physiol. 2020 Apr;235(4):3657-3668. doi: 10.1002/jcp.29255. Epub 2019 Oct 3.
10
18-Fluorodeoxyglucose Positron Emission Tomography Predicts Recurrence in Resected Pancreatic Ductal Adenocarcinoma.18F-氟代脱氧葡萄糖正电子发射断层扫描预测可切除胰腺导管腺癌的复发。
J Gastrointest Surg. 2018 Feb;22(2):279-287. doi: 10.1007/s11605-017-3627-3. Epub 2017 Nov 8.
局部晚期胰腺癌:Folfirinox 新辅助治疗使 60%的患者获得可切除性。
Ann Surg. 2016 Sep;264(3):457-63. doi: 10.1097/SLA.0000000000001850.
4
Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer.纳布紫杉醇联合吉西他滨用于未经化疗的日本转移性胰腺癌患者的I/II期研究。
Cancer Chemother Pharmacol. 2016 Mar;77(3):595-603. doi: 10.1007/s00280-016-2972-3. Epub 2016 Feb 3.
5
Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.一线FOLFIRINOX方案治疗初始不可切除的局部进展期胰腺癌后的可切除性:单中心经验
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1212-20. doi: 10.1245/s10434-015-4851-2. Epub 2015 Sep 8.
6
Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria.手术并发症的扩展Clavien-Dindo分类:日本临床肿瘤学会术后并发症标准
Surg Today. 2016 Jun;46(6):668-85. doi: 10.1007/s00595-015-1236-x. Epub 2015 Aug 20.
7
Increase in peritoneal recurrence induced by intraoperative hemorrhage in gastrectomy.胃癌根治术中出血所致腹膜复发的增加
Ann Surg Oncol. 2015 Mar;22(3):758-64. doi: 10.1245/s10434-014-4060-4. Epub 2014 Sep 9.
8
Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer.FOLFIRINOX 方案治疗化疗初治的转移性胰腺癌日本患者的 II 期研究。
Cancer Sci. 2014 Oct;105(10):1321-6. doi: 10.1111/cas.12501. Epub 2014 Sep 29.
9
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.白蛋白结合型紫杉醇联合吉西他滨治疗胰腺癌可提高生存率。
N Engl J Med. 2013 Oct 31;369(18):1691-703. doi: 10.1056/NEJMoa1304369. Epub 2013 Oct 16.
10
Impact of tumor grade on pancreatic cancer prognosis: validation of a novel TNMG staging system.肿瘤分级对胰腺癌预后的影响:新型 TNMG 分期系统的验证。
Ann Surg Oncol. 2013 Dec;20(13):4322-9. doi: 10.1245/s10434-013-3159-3. Epub 2013 Aug 14.